

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

AN ACT relating to public health and safety; authorizing physicians to recommend and perform stem cell therapy on patients as specified; allowing health care insurers to cover stem cell therapy as specified; prohibiting the state board of medicine from taking action against a physician's license due to the use or promotion of stem cell therapy; prohibiting the state of Wyoming from denying patients access to stem cell therapy; providing that no cause of action is created against a person properly performing stem cell therapy; requiring compliance as specified; amending the powers of the Wyoming state board of medicine; providing definitions; and providing for an effective date.

*Be It Enacted by the Legislature of the State of Wyoming:*

**Section 1.** W.S. 35-4-1101 through 35-4-1106 are created to read:

ARTICLE 11  
STEM CELL FREEDOM ACT

**35-4-1101. Short title.**

This act shall be known and may be cited as the "Stem Cell Freedom Act."

**35-4-1102. Definitions.**

(a) As used in this article:

(i) "Current good manufacturing practices" means the quality, safety and manufacturing practice standards employed under this act that are consistent with applicable federal law;

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

(ii) "Institutional review board" means a group duly constituted and currently registered in accordance with applicable federal law that provides initial approval and continuing oversight of the stem cell therapies being offered under this act, including adverse event reporting and the approval of a form to be used for informed consent between a physician and patient or the patient's legal representative prior to the use of stem cell therapy;

(iii) "Investigational drug, biological product or device" means a drug, biological product or device that has successfully completed phase one (1) of a clinical trial but has not yet been approved for general use by the United States food and drug administration and remains under investigation in a clinical trial;

(iv) "Physician" means a person licensed to practice medicine by the state board of medicine pursuant to title 33, chapter 26 of the Wyoming statutes. "Physician" shall not include a physician assistant as defined by W.S. 33-26-501(a)(iii);

(v) "Stem cell therapy" means treatment involving the use of autologous mesenchymal stem cells, including but not limited to the collection, processing, cultural expansion, manufacturing, storage and therapeutic use of stem cells. "Stem cell therapy" shall not include, whether directly or indirectly, the use of any biological material derived from an abortion;

(vi) "This act" means W.S. 35-4-1101 through 35-4-1106.

**35-4-1103. Access to stem cell therapy; conditions; insurance coverage.**

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

(a) Notwithstanding W.S. 35-7-118 and any other law to the contrary, a patient may receive, and a physician may perform, stem cell therapy that has not been approved by the United States food and drug administration if:

(i) The therapy is conducted in accordance with a current institutional review board approval or is an investigational drug, biological product or device;

(ii) The stem cells are manufactured and handled in accordance with current good manufacturing practice standards;

(iii) A physician-patient relationship exists between the physician administering the stem cell therapy and the person receiving the therapy;

(iv) The physician is registered with the Wyoming state board of medicine to provide stem cell therapy pursuant to this act;

(v) The patient or legally recognized representative of the patient has provided written informed consent acknowledging:

(A) The nature and character of the proposed stem cell therapy;

(B) That stem cell therapy is not approved by the United States food and drug administration;

(C) The potential benefits, risks and complications associated with stem cell therapy and the procedure to be performed; and

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

(D) The financial responsibility of the patient or legally recognized representative of the patient in paying for the stem cell therapy to be received.

(b) Stem cell therapy provided pursuant to this act shall be administered by a physician or under the direct supervision of a physician. Activities other than the actual administration of the stem cells to the patient shall be supervised by a physician.

(c) No person authorized under this act to perform stem cell therapy or manufacture stem cells shall be obligated by this act to provide stem cell therapy or stem cells but may do so according to the person's own discretion and judgment.

(d) A health carrier as defined by W.S. 26-13-303(a)(iii) may but shall not be required to provide coverage for costs associated with stem cell therapy.

(e) This act shall not prohibit the performing of any stem cell therapy or activity otherwise allowed by law. A person shall not perform, advertise or represent that the person is providing stem cell therapy under this act if the person does not comply with the provisions of this act.

**35-4-1104. Action against physician license prohibited.**

Notwithstanding any other provision of law, the Wyoming state board of medicine shall not revoke, fail to renew, suspend or take any other action against a physician's license based solely on the physician's recommendations to a patient regarding access to or treatment with stem cell

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

therapy or the performance of stem cell therapy, provided that the recommendations or procedures are consistent with medical standards of care and that the physician is registered with the Wyoming state board of medicine to provide stem cell therapy under this act.

**35-4-1105. Access to stem cell therapy.**

An official, employee or agent of this state or any political subdivision of this state shall not prohibit or attempt to prohibit a patient's access to stem cell therapy. Counseling, advice or a recommendation consistent with medical standards of care from a licensed health care provider shall not constitute a violation of this section.

**35-4-1106. No cause of action created.**

This act shall not create a private cause of action against any person involved in the care of any patient using stem cell therapy or the manufacturing of stem cells if the person is complying with the requirements of this act and medical standards of care.

**Section 2.** W.S. 33-26-202(b) by creating a new paragraph (xx) is amended to read:

**33-26-202. Board; duties; general powers.**

(b) The board is empowered and directed to:

(xx) Operate and publish a public registry of qualified physicians registered to perform stem cell therapy pursuant to the Stem Cell Freedom Act.

ORIGINAL SENATE  
FILE NO. SF0048

ENGROSSED

ENROLLED ACT NO. 31, SENATE

SIXTY-EIGHTH LEGISLATURE OF THE STATE OF WYOMING  
2026 BUDGET SESSION

**Section 3.** This act is effective July 1, 2026.

(END)

\_\_\_\_\_  
Speaker of the House

\_\_\_\_\_  
President of the Senate

\_\_\_\_\_  
Governor

TIME APPROVED: \_\_\_\_\_

DATE APPROVED: \_\_\_\_\_

I hereby certify that this act originated in the Senate.

\_\_\_\_\_  
Chief Clerk